Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $0.91, $0.08 worse than the analyst estimate of $0.99. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $82.94 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.